Login to Your Account

Financings Roundup

Seattle Genetics Boosts Antibody Work with $90M Public Offering

By Jennifer Boggs

Tuesday, January 22, 2008
Coming off a year in which it advanced its multi-drug clinical-stage pipeline and scored a major deal with Genentech Inc., Bothell, Wash.-based Seattle Genetics Inc. has given no indication of slowing down, as it starts 2008 with a $90 million public offering. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription